pdufa.bio
CalendarDecisionsApprovals/yrTrial oddsLearnResearchMethodology
Home › PDUFA Calendar › LNTH

LNTH PDUFA Date: Florquinitau (MK-6240)

FDA decision (PDUFA) target 2026-08-13 · Lantheus Holdings Inc. · Alzheimer's disease

LNTH run-up into the PDUFA (last ~120 days)

$105.03$72.56
Price path to 2026-06-19. Green = local high, red = low/sell-off. Historical price action, not a forecast.

Key facts

FDA PDUFA target date2026-08-13
Drug / candidateFlorquinitau (MK-6240)
IndicationAlzheimer's disease
CompanyLantheus Holdings Inc.
Market-cap tierMid
Cohort decision-day move (history)±2% median
ClinicalTrials.gov—

New to FDA decisions? Read what a PDUFA date is and how often the FDA approves drugs.

Track this live → price, options (expected move & IV) and the full dashboard
Opens the pdufa.bio app (private beta)

FAQ

When is the LNTH PDUFA date?
The FDA PDUFA target date for LNTH (Lantheus Holdings Inc.) is 2026-08-13 for Florquinitau (MK-6240). Dates are company/FDA-sourced and can slip — verify against primary filings.
What is LNTH's drug Florquinitau (MK-6240)?
Florquinitau (MK-6240) is Lantheus Holdings Inc.'s candidate under FDA review for Alzheimer's disease.
What typically happens to a mid-cap stock into a PDUFA date?
Historically, mid-cap names had a median decision-day move around ±2% (694-PDUFA cohort, 2024–26). This is historical context by market-cap tier, not a prediction for this drug.